Becton, Dickinson and Company $BDX Shares Purchased by NEOS Investment Management LLC

NEOS Investment Management LLC raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 44.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 39,656 shares of the medical instruments supplier’s stock after buying an additional 12,113 shares during the quarter. NEOS Investment Management LLC’s holdings in Becton, Dickinson and Company were worth $7,422,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. Heartland Advisors Inc. boosted its stake in shares of Becton, Dickinson and Company by 23.2% during the third quarter. Heartland Advisors Inc. now owns 89,168 shares of the medical instruments supplier’s stock valued at $16,690,000 after acquiring an additional 16,805 shares during the last quarter. Rothschild Investment LLC grew its holdings in shares of Becton, Dickinson and Company by 19.2% during the third quarter. Rothschild Investment LLC now owns 868 shares of the medical instruments supplier’s stock worth $162,000 after buying an additional 140 shares in the last quarter. M&G PLC raised its position in shares of Becton, Dickinson and Company by 4.9% in the third quarter. M&G PLC now owns 935,480 shares of the medical instruments supplier’s stock valued at $174,935,000 after buying an additional 43,404 shares during the last quarter. Zions Bancorporation National Association UT boosted its position in Becton, Dickinson and Company by 33.5% during the third quarter. Zions Bancorporation National Association UT now owns 813 shares of the medical instruments supplier’s stock worth $152,000 after acquiring an additional 204 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in Becton, Dickinson and Company by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock worth $6,074,750,000 after acquiring an additional 147,041 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Up 3.1%

NYSE:BDX opened at $182.82 on Thursday. The business’s 50-day moving average is $198.01 and its two-hundred day moving average is $192.26. The firm has a market capitalization of $52.06 billion, a PE ratio of 29.82, a price-to-earnings-growth ratio of 2.32 and a beta of 0.25. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $185.02. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.15 billion. During the same period last year, the business earned $3.43 EPS. The business’s revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Becton, Dickinson and Company declared that its board has approved a share buyback plan on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of recent analyst reports. Zacks Research downgraded Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 11th. Morgan Stanley upped their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Bank of America raised their target price on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Barclays began coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. They set an “overweight” rating and a $202.00 price target for the company. Finally, Wells Fargo & Company decreased their price target on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 10th. Five analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $195.46.

Insider Transactions at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the transaction, the director directly owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 3,416 shares of company stock worth $675,557 in the last three months. 0.40% of the stock is currently owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.